Viking Therapeutics CEO flags risk to monthly weight-loss shot ambitions
Yahoo Finance report examines whether the biotech can compete with large pharma on long-interval obesity injectables.
TR
By Tom Reyes · Markets Editor
Sep 15 02:03 ETSource: Yahoo Finance
The wire
- 01Coverage examined Viking Therapeutics' monthly weight-loss injection strategy and a risk its CEO says could derail it.
- 02Long-interval dosing is a key differentiator as obesity drug competition intensifies.
- 03The specific risk, trial timelines and data readouts are not detailed in the excerpt.
From the source
Read at news.google.comCan Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It